UCB's Neupro re-launched in USA for Parkinson's and RSL
Belgium drugmaker UCB (Euronext Brussels: UCB) said yesterday that its Neupro (rotigotine transdermal system) is now available in US pharmacies. Neupro was approved by the US Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson’s disease (PD) and moderate-to-severe primary Restless Legs Syndrome (RLS; The Pharma Letter April 3).
The company said that Neupro improves motor function and activities of daily living in patients with PD and provides effective symptom relief for patients with RLS. Neupro is a once-daily patch that provides continuous delivery of the dopamine agonist rotigotine for 24 hours. Over 100,000 patients have been treated with Neupro worldwide, and seven clinical trials for the approved indications have demonstrated efficacy, safety and tolerability.
Re-launch follows 2007 withdrawal
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze